GTHR Stock Price, Chart, Stats & News

GeneThera, Inc.
Save
GeneThera, Inc. (GTHR) does not currently pay a dividend.
3,533
Market cap
–
Current P/E
–
Forward P/E
GTHR chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
GeneThera, Inc. is a biotechnology firm dedicated to crafting advanced diagnostic tools and therapeutic solutions for diseases that can transfer from animals to humans (zoonotic diseases). The company's portfolio includes treatments for a variety of these conditions, such as COVID-19, and illnesses like paratuberculosis (Johne's disease), currently in its Stage III clinical phase, as well as mad cow and chronic wasting diseases, and common bacterial infections like E.coli and salmonella. Furthermore, GeneThera is developing a vaccine specifically targeting Mycobacterium avium subspecies paratuberculosis bacteria.
Similar securities
Based on sector and market capitalization
Report issue











